Newswise — November 29, 2022 – For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of cancer-related death compared to heat-based thermal ablation, reports a preliminary study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"In contrast, for patients with RCCs smaller than 3 centimeters, either cold-based or heat-based therapy is just as effective in reducing cancer-specific mortality," comments lead author Gabriele Sorce, MD, of IRCCS San Raffaele Scientific Institute, Milan. "The findings may help us to better tailor the choice of ablation technique for patients with small RCCs."
Lower risk of cancer death with cryoablation versus heating
Renal cell carcinoma is the most common type of kidney cancer. For patients with early-stage RCCs smaller than 4 cm, an increasingly popular treatment option is destroying the cancer by freezing it or heating it. For these clinical stage T1a RCCs, this cancer-destroying procedure, called ablation, can provide high survival rates without the need for more extensive kidney surgery.
However, the outcomes of ablation appear "less favorable" for a subset of patients with clinical stage T1a RCCs: those whose tumors are between 3 and 4 cm in size. Current European guidelines recommend cryoablation over heat-based thermal ablation for this cancers measuring 3 to 4 cm, while US guidelines state that either treatment can be used. Both sets of guidelines state that either freezing or heating can be used for T1a RCCs measuring 3 cm or smaller.
To clarify the issue, an international research group analyzed patients with stage T1a RCCs treated with freezing or heating between 2004 and 2018. Patients were drawn from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. The study focused on two matched groups of patients with cancers measuring between 3 and 4 cm: 757 treated with cryoablation and 388 treated with heat-based thermal ablation.
Median age at treatment was 71 years. Follow-up data on cancer-specific mortality – the risk of death from kidney cancer, excluding other causes of death – were available for 422 patients treated with freezing and 238 treated with heating.
Eight years after treatment, estimated cancer-specific mortality among patients with RCCs measuring 3 to 4 cm was 8.5% for patients treated with cryoablation versus 12.9% for those undergoing heat-based thermal ablation. With both treatments, about 40% of patients died from causes other than cancer.
Implications for treatment decisions in 'small, potentially curable' kidney cancers
After adjustment for non-cancer-related death and other characteristics, patients undergoing heat-based thermal ablation for RCCs between 3 and 4 cm were twice as likely to die of kidney cancer. In contrast, for patients with cancers smaller than 3 cm, estimated cancer-specific mortality was similar between groups: 6.8% after cryoablation and 6.1% after heat-based thermal ablation.
The study is one of the first to directly compare clinical outcomes for freezing versus heating in patients with stage T1a RCCs measuring between 3 and 4 cm. The results suggest that heat-based thermal ablation has "a highly statistically significant and clinically meaningful" disadvantage in terms of the long-term risk of death from kidney cancer, compared to cryoablation.
"Conversely, in patients with tumor size 3 centimeters or smaller, either ablation technique is equally valid," says Dr. Sorce. "We believe our findings have important implications for clinical decision making and informed consent for patients with these small, potentially curable kidney cancers"
Read [Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma]
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.